Creative Medical Technology Holdings has reported promising three-year follow-up data from its pioneering StemSpine pilot study, marking a significant advancement in cell-based therapy for chronic lower back pain management.
The study, which evaluated the company's proprietary AlloStem cell treatment, demonstrated remarkable success in reducing patients' dependence on opioid medications. More than 90% of participants reported complete cessation of opioid use for pain management at the three-year follow-up mark, addressing a critical concern in chronic pain treatment.
Clinical Outcomes and Patient Benefits
The data revealed substantial improvements across multiple efficacy measures. Patients maintained an 80% reduction in pain scores throughout the follow-up period, indicating the treatment's durability. Functional mobility, as measured by the Oswestry Disability Index (ODI), showed greater than 60% improvement, suggesting significant enhancement in patients' quality of life and daily activities.
Safety Profile and Treatment Durability
The StemSpine procedure demonstrated an exceptional safety record, with no serious adverse events reported throughout the three-year follow-up period. The durability of the treatment was particularly noteworthy, with only one patient requiring reintervention during this extended observation period.
Implications for Chronic Pain Management
These results represent a potentially transformative approach to treating chronic lower back pain, particularly in the context of the ongoing opioid crisis. The study's outcomes suggest that cell-based therapy could offer a viable alternative to long-term opioid use, addressing both pain management and functional improvement while avoiding the risks associated with opioid dependency.
Timothy Warbington, President and CEO of Creative Medical Technology, stated, "The three-year follow-up data strongly validates our approach to treating chronic lower back pain. The sustained reduction in opioid use and persistent improvement in pain scores demonstrate the potential long-term benefits of our AlloStem cell therapy."
Treatment Protocol and Assessment
The StemSpine procedure involves the administration of AlloStem cells, with patient progress monitored through standardized pain assessments and functional mobility measures. The sustained positive outcomes at three years post-treatment suggest the potential for long-term efficacy without the need for repeated interventions.
